Urovant Sciences

$7.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (1.15%) Today
+$0.01 (0.13%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell UROV and other stocks, options, ETFs, and crypto commission-free!

About UROV

Urovant Sciences Ltd. Common Stock, also called Urovant Sciences, is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Read More Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.

Employees
Headquarters
London, Greater London
Founded
2016
Market Cap
239.69M
Price-Earnings Ratio
Dividend Yield
Average Volume
40.53K
High Today
$7.90
Low Today
$7.75
Open Price
$7.79
Volume
2.61K
52 Week High
$14.49
52 Week Low
$4.06

Collections

UROV Earnings

-$1.23
-$1.08
-$0.92
-$0.77
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.08 per share
Actual
-$0.94 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.